A systematic review of moral reasons on orphan drug reimbursement

BACKGROUND: The number of market approvals of orphan medicinal products (OMPs) has been increasing steadily in the last 3 decades. While OMPs can offer a unique chance for patients suffering from rare diseases, they are usually very expensive. The growing number of approved OMPs increases their budg...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmermann, Bettina M., Eichinger, Johanna, Baumgartner, Matthias R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247078/
https://www.ncbi.nlm.nih.gov/pubmed/34193232
http://dx.doi.org/10.1186/s13023-021-01925-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247078/
https://www.ncbi.nlm.nih.gov/pubmed/34193232
http://dx.doi.org/10.1186/s13023-021-01925-y

Ejemplares similares